-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Sofosbuvir impurity I
Category | Hepatitis C Virus (HCV) |
CAS | 2164516-85-0 |
Description | Sofosbuvir impurity I is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity. |
Product Information
Synonyms | Ethyl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-4-fluoro-3-hydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate; Uridine, 2'-deoxy-5'-O-[(S)-[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-2'-fluoro-2'-methyl-; Sofosbuvir Impurity 19 |
IUPAC Name | ethyl (2S)-2-[(S)-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate |
Molecular Weight | 515.43 |
Molecular Formula | C21H27FN3O9P |
Canonical SMILES | CCOC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 |
InChI | InChI=1S/C21H27FN3O9P/c1-4-31-18(28)13(2)24-35(30,34-14-8-6-5-7-9-14)32-12-15-17(27)21(3,22)19(33-15)25-11-10-16(26)23-20(25)29/h5-11,13,15,17,19,27H,4,12H2,1-3H3,(H,24,30)(H,23,26,29)/t13-,15+,17+,19+,21+,35-/m0/s1 |
InChIKey | HRGZELWFPQCNNG-NQVPMCNCSA-N |
Purity | ≥95% |
Density | 1.4±0.1 g/cm3 |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
Complexity | 884 |
Exact Mass | 515.14689461 |
Target | HCV |
XLogP3-AA | 0.6 |